Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy

被引：2
|
作者：
Cho, B. C. [1 ]
Aguado de la Rosa, C. [2 ]
Vila, L. [3 ]
Isla, D. [4 ]
Oliveira, J. [5 ]
de Castro Carpeno, J. [6 ]
Tomova, A. [7 ]
Kim, T. M. [8 ]
Blasco Cordellat, A. [9 ]
Bauchet, A-L. [10 ]
Soufflet, C. [11 ]
Bensfia, S. [12 ]
Dy, G. [13 ]
机构：
[1] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Parc Tauli Hosp Univ, Barcelona, Spain
[4] Hosp Clin Lozano Blesa, Zaragoza, Spain
[5] Inst Portugues Oncol Porto Francisco Gentil EPE, Porto, Portugal
[6] Hosp Univ La Paz, Madrid, Spain
[7] Complex Oncol Ctr Plovdiv, Plovdiv, Bulgaria
[8] Seoul Natl Univ Hosp, Seoul, South Korea
[9] Hosp Univ Valencia, Valencia, Spain
[10] Sanofi, Chilly Mazarin, France
[11] Sanofi, Boulogne, France
[12] Sanofi, Cambridge, MA USA
[13] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1965
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364TiP
引用
收藏
页码：S1034 / S1035
页数：2
相关论文
共 50 条
  • [41] Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer
    Lee, Youngjoo
    Joo, Jungnam
    Lee, You Jin
    Lee, Eun Kyung
    Park, Sohyun
    Kim, Tae-Sung
    Lee, Soo-Hyun
    Kim, So Young
    Wie, Gyung-Ah
    Park, Minjoung
    Kim, Mi-Jung
    Lee, Jin Soo
    Han, Ji-Youn
    LUNG CANCER, 2021, 151 : 8 - 15
  • [42] A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non-small-cell lung cancer.
    Reuss, Joshua E.
    Wonser, Dann
    Smith, Kellie Nicole
    Ahn, Jaeil
    Byers, Stephen
    Creswell, Karen
    Kim, Chul
    Thompson, Jillian
    Crawford, Jenny
    Cohen, Emil
    Zeck, Jay
    Gutierrez, Martin
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Final Report of an Open-Label Phase II Trial of Bevacizumab Plus Docetaxel and Gemcitabine in Metastatic, Previously Untreated Non-squamous Non-small Cell Lung Cancer (NSCLC)
    Pennell, N. A.
    Kalmadi, S. R.
    Shapiro, M.
    Daw, H.
    Rodriguez, C.
    Haddad, A.
    Samsa, J.
    Elson, P.
    Ma, P.
    Dowlati, A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S247 - S247
  • [44] Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05
    Zappa, F.
    Droege, C.
    Betticher, D.
    von Moos, R.
    Brutsche, M.
    Baty, F.
    Bubendorf, L.
    Ochsenbein, A.
    Leibundgut, Oppliger E.
    Gautschi, O.
    Froesch, P.
    Stahel, R.
    Rauch, D.
    Schmid, P.
    Mayer, M.
    Crowe, S.
    Brauchli, P.
    Ribi, K.
    Pless, M.
    ONKOLOGIE, 2011, 34 : 122 - 122
  • [45] Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study
    Ahn, Myung-Ju
    Lim, Sung Hee
    Sun, Jong -Mu
    Choi, Yoon-La
    Kim, Hye Ryun
    Ahn, Soo-min
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Kim, Joo Hang
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S16 - S16
  • [46] Nivolumab as maintenance therapy following platinum-based chemotherapy in non-small cell lung cancer patients after tyrosine kinase inhibitor therapy: A single-arm, open-label, phase 2 trial
    Kim, Jiwon
    Ji, Wonjun
    Choi, Chang Min
    Lee, Jae Cheol
    RESPIROLOGY, 2023, 28 : 307 - 307
  • [47] Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
    Helei Hou
    Yongjie Wang
    Dantong Sun
    Jingjuan Zhu
    Man Jiang
    Xuchen Zhang
    Na Zhou
    Chuantao Zhang
    Tianjun Li
    Xiaochun Zhang
    Investigational New Drugs, 2023, 41 : 86 - 92
  • [48] Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China
    Hou, Helei
    Wang, Yongjie
    Sun, Dantong
    Zhu, Jingjuan
    Jiang, Man
    Zhang, Xuchen
    Zhou, Na
    Zhang, Chuantao
    Li, Tianjun
    Zhang, Xiaochun
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 86 - 92
  • [49] CCTG BR.34: A randomized trial of durvalumab and tremelimumab plus /- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
    Leighl, Natasha B.
    Laurie, Scott Andrew
    Goss, Glenwood D.
    Hughes, Brett Gordon Maxwell
    Stockler, Martin R.
    Tsao, Ming Sound
    Kulkarni, Swati
    Blais, Normand
    Joy, Anil A.
    Mates, Mihaela
    Rana, Punam
    Yadav, Sunil
    Underhill, Craig
    Lee, Christopher W.
    Bradbury, Penelope Ann
    Hiltz, Andrea
    Dancey, Janet
    Ding, Keyue
    Badillo, Francisco Emilio Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] A Phase 2 Single-Arm Trial of High-Dose Precision Targeted Radiation Therapy Added to Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
    Gensheimer, Michael F.
    Kotha, Nikhil, V
    Vitzthum, Lucas K.
    Chin, Alexander L.
    Jackson, Scott
    Van't Erve, Iris
    Pratapneni, Aniket
    Le-Budka, My-Linh
    Wong, Samantha
    Brown, Eleanor
    Barnick, Katy
    Wakelee, Heather A.
    Das, Millie
    Ramchandran, Kavitha J.
    Myall, Nathaniel J.
    Padda, Sukhmani
    Marquez, Carol M.
    Million, Lynn
    Chen, Thomas T.
    Man, Martha C.
    Cabebe, Elwyn C.
    Chen, May Cheng-Su
    Hiniker, Susan
    Hancock, Steven L.
    Swift, Patrick S.
    Diehn, Maximilian
    Loo, Billy W.
    Neal, Joel W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (03): : 711 - 719
12345